波士顿科学公司最新预测显示,2026年第一季度净销售额预计将实现10.5%至12.0%的同比增长。这一数据基于报告基准计算,反映出公司在心血管介入、神经调节等核心业务领域的持续增长动能。
此次业绩指引凸显了公司创新产品管线带来的商业化成效,同时得益于全球市场对微创医疗解决方案的强劲需求。分析师认为该增长区间符合市场预期,或将进一步巩固其在医疗器械行业的领先地位。
波士顿科学公司最新预测显示,2026年第一季度净销售额预计将实现10.5%至12.0%的同比增长。这一数据基于报告基准计算,反映出公司在心血管介入、神经调节等核心业务领域的持续增长动能。
此次业绩指引凸显了公司创新产品管线带来的商业化成效,同时得益于全球市场对微创医疗解决方案的强劲需求。分析师认为该增长区间符合市场预期,或将进一步巩固其在医疗器械行业的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.